{"prompt": "['within 2 working days to Merk Global Safety. (Attn: Worldwide Product Safety; FAX 215-', '661-6229).', 'For the time period beginning when the consent form is signed until treatment allocation, any', 'ECI, or follow up to an ECI, that occurs to any participant must be reported within 2 working', 'days to Merk Global Safety if it causes the participant to be excluded from the trial, or is the', 'result of a protocol-specified intervention, including but not limited to washout or', 'discontinuation of usual therapy, diet, placebo treatment or a procedure.', 'For the time period beginning at treatment allocation through 90 days following cessation of', 'treatment, or 30 days following cessation of treatment if the participant initiates new', 'anticancer therapy, whichever is earlier, any ECI, or follow up to an ECI, whether or not', 'related to Merk product, must be reported within 2 working days to Merk Global Safety.', 'Events of clinical interest for this trial include:', '1. an overdose of Merk product, as defined in Section 7.2.1 - Definition of an Overdose for', 'This Protocol and Reporting of Overdose to the Supporter, that is not associated with clinical', 'symptoms or abnormal laboratory results.', '2. an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of', 'normal and an elevated total bilirubin lab value that is greater than or equal to 2X the upper', 'limit of normal and, at the same time, an alkaline phosphatase lab value that is less than 2X', 'the upper limit of normal, as determined by way of protocol-specified laboratory testing or', 'unscheduled laboratory testing.*', '*Note: These criteria are based upon available regulatory guidance documents. The', 'purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require', 'an additional evaluation for an underlying etiology.', '7.2.4 Evaluating Adverse Events', 'An investigator who is a qualified physician will evaluate all adverse events according to the', 'NCI Common Terminology for Adverse Events (CTCAE), version 4.0. Any adverse event', 'which changes CTCAE grade over the course of a given episode will have each change of', 'grade recorded on the adverse event case report forms/worksheets.', 'All adverse events regardless of CTCAE grade must also be evaluated for seriousness.', '60']['Table 10. Evaluating Adverse Events', 'An investigator who is a qualified physician, will evaluate all adverse events as to:', 'V4.0 CTCAE', 'Grade 1', 'Mild; asymptomatic or mid symptoms; clinical or diagnostic observations only; intervention not indicated.', 'Grading', 'Grade 2', 'Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.', 'Grade 3', 'Severe or medically significant but not immediately life-threatening; hospitalization or prolongation or hospitalization indicated;', 'disabling; limiting self-care ADL.', 'Grade 4', 'Life threatening consequences; urgent intervention indicated.', 'Grade 5', 'Death related to AE', 'Seriousness', 'A serious adverse event is any adverse event occurring at any dose or during any use of Merk product that:', 'Results in death; or', '+Is life threatening; or places the participant, in the view of the investigator, at immediate risk of death from the event as it occurred (Note: This does not include an', 'adverse event that, had it occurred in a more severe form, might have caused death.);', 'or', \"*Results in a persistent or significant disability/incapacity (substantial disruption of one's ability to conduct normal life functions); or\", 'Results in or prolongs an existing inpatient hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay, even if the', 'hospitalization', 'is', 'a', 'precautionary measure for continued observation. (Note: Hospitalization for an elective procedure to treat a pre-existing condition that has not', 'worsened is not a serious adverse event. A pre-existing condition is a clinical condition that is diagnosed prior to the use of a Merk product and is documented in', \"the patient's medical history.); or\", '+Is a congenital anomaly/birth defect (in offspring of participant taking the product regardless of time to diagnosis);or', 'Is a new cancer (that is not a condition of the study) (although not serious per ICH definition, is reportable to the Sponsor within 24 hours and to Merk within 2', 'working days to meet certain local requirements); or', '61']\n\n###\n\n", "completion": "END"}